How common are local and systemic reactions to the mRNA new crown vaccine?

In addition to clinical trials, the reactogenicity of the new crown vaccine, including the monitoring of local and systemic reactions, will help medical practitioners and the public to have a more comprehensive understanding of the relevant information about the new crown vaccine.

Based on this system, the US Centers for Disease Control and Prevention recently published an important study in the Journal of the American Medical Association (JAMA), analyzing the local and systemic response data actively reported by 3.

Screenshot source: JAMA

The v-safe monitoring system is voluntarily registered by vaccinators, and online health surveys are completed regularly through mobile notification messages.

This analysis covers the local and systemic response data collected by the v-safe system from December 14, 2020 to February 28, 2021, and people reported within 7 days after being vaccinated with Pfizer/BioNTech and Moderna's new crown vaccines (Johnson & Johnson single dose The new crown vaccine was authorized by the US FDA for emergency use at the end of February, so it was not included in this analysis).

As of February 21, 2021, more than 46 million people have received at least one dose of mRNA for the new crown vaccine.

The data of millions of vaccinators participating in the v-safe monitoring show that pain at the injection site is common after v-safe vaccination.

Most vaccinators reported injection site reactions (first dose: 70.

After the first dose of the vaccine, the most commonly reported local and systemic reactions include: pain at the injection site (67.

For both mRNA vaccines, the reactogenicity after the second dose was significantly stronger, especially the incidence of systemic reactions was significantly higher, including pain at the injection site (72.

▲Local and systemic reactions reported 0-7 days after inoculation of the mRNA new crown vaccine (data source: reference [1]; table compilation: new medical perspectives)

Among the two vaccines, Moderna vaccinators reported more post-vaccination reactions, especially after the second dose.

Further analysis of populations <65 and ≥65 years of age showed that the difference in vaccine reactogenicity was consistent with the overall findings, but people ≥65 years of age reported fewer local and systemic reactions.

The research team pointed out in the paper that the frequency of reactions reported by these vaccinators in the real world is consistent with the results observed in clinical trials.

Reference

[1] Chapin-Bardales J, et al.